Literature DB >> 2869486

Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.

U D Staerz, M J Bevan.   

Abstract

Previous studies have shown that heteroconjugates of monoclonal antibodies in which one of the component antibodies is directed at the T-cell receptor and the other is directed against any chosen site can focus effector T cells to function at the targeted site. We report here the production of a hybrid hybridoma cell line, H1.10.1.6, which secretes large amounts of a bispecific hybrid antibody of the IgG2a class, that can focus T-cell activity. The parental hybridoma lines for the secondary fusion were F23.1, which secretes an antibody specific for an allotypic determinant on the T-cell receptor of most mouse strains, and 19E12, secreting an anti-Thy-1.1 antibody. The bispecific hybrid antibody was partially purified by hydroxylapatite chromatography and characterized by isoelectric focusing. It efficiently targets Thy-1.1-expressing tumor cells for lysis by F23.1 receptor-positive cytotoxic T-cell clones in vitro. Such hybrid antibodies produced by hybrid hybridoma cell lines may have application in the therapeutic targeting of tumors or sites of viral infections for attack by T cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869486      PMCID: PMC323094          DOI: 10.1073/pnas.83.5.1453

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Recombination of a mixture of univalent antibody fragments of different specificity.

Authors:  A NISONOFF; M M RIVERS
Journal:  Arch Biochem Biophys       Date:  1961-05       Impact factor: 4.013

3.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

4.  Specific interaction between VH and VL regions of human monoclonal immunoglobulins.

Authors:  C De Préval; M Fougereau
Journal:  J Mol Biol       Date:  1976-04-15       Impact factor: 5.469

5.  Specific in vivo localization of monoclonal antibodies directed against the Thy 1.1 antigen.

Authors:  L L Houston; R C Nowinski; I D Bernstein
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

6.  Somatic cell hybridization of mouse myeloma cells.

Authors:  D H Margulies; W M Kuehl; M D Scharff
Journal:  Cell       Date:  1976-07       Impact factor: 41.582

7.  Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

Authors:  I D Bernstein; M R Tam; R C Nowinski
Journal:  Science       Date:  1980-01-04       Impact factor: 47.728

8.  Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody.

Authors:  J P Allison; B W McIntyre; D Bloch
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

9.  Use of hybrid antibody with anti-gamma-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy.

Authors:  U Hämmerling; T Aoki; E de Harven; E A Boyse; L J Old
Journal:  J Exp Med       Date:  1968-12-01       Impact factor: 14.307

10.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  39 in total

1.  Altered reactivity of immunoglobulin produced by human-human hybridoma cells transfected by pSV2-neo gene.

Authors:  H Tachibana; K Akiyama; S Shirahata; H Murakami
Journal:  Cytotechnology       Date:  1991-07       Impact factor: 2.058

Review 2.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

3.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

4.  Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.

Authors:  S A Möller; R A Reisfeld
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 5.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

6.  A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro.

Authors:  A Fernandez-Sesma; J L Schulman; T M Moran
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Response to "in vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement".

Authors:  Kota Iwahori; Xiao-Tong Song; Stephen Gottschalk
Journal:  Mol Ther       Date:  2015-04       Impact factor: 11.454

8.  A New Agent in the Strategy to Cure AIDS.

Authors:  John A Zaia
Journal:  Mol Ther       Date:  2016-11       Impact factor: 11.454

Review 9.  Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Authors:  Daniel G Guy; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.